MUTATION AND EXPRESSION OF THE P53 GENE IN HUMAN-MALIGNANT MELANOMA

被引:143
|
作者
ALBINO, AP
VIDAL, MJ
MCNUTT, NS
SHEA, CR
PRIETO, VG
NANUS, DM
PALMER, JM
HAYWARD, NK
机构
[1] Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center Cornell University Medical College, Queensland Institute of Medical Research, New York, NY
关键词
MALIGNANT MELANOMA; MELANOCYTE; MUTATION; P53;
D O I
10.1097/00008390-199402000-00006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Derangement of the p53 tumor suppressor gene has been implicated in the aetiology of a wide range of human neoplasias. We have previously determined that overexpression and mutation of the p53 gene in cultured metastatic melanomas is low (11%). However, two recent immunohistochemical studies have reported that >85% of malignant melanoma specimens overexpress mutated p53 protein. In an effort to resolve this contradiction in the published literature, we have re-evaluated a range of cultured and non-cultured melanocytic lesions for the occurrence of point mutations in the p53 gene using DNA- and RNA-dependent single strand conformation polymorphism (RNA-SSCP) and direct DNA sequencing of polymerase chain reaction (PCR) amplified DNA, and overexpression of the p53 protein using immunohistochemistry. We found point mutations in 25% (9 of 36) of cultured melanomas and 0% in 34 fresh melanoma biopsies; however, increased p53 expression was found in 42% of paraffin-embedded melanoma specimens and 7% of benign lesions. The low frequency of p53 point mutations and high frequency of p53 expression suggests that derangement of the p53 gene by point mutations is not a common perturbation in the majority of melanoma cells, and that overexpression of p53 in this tumour type is due to a mechanism other than point mutation.
引用
收藏
页码:35 / 45
页数:11
相关论文
共 50 条
  • [31] p53 protein expression and gene mutation in phyllodes tumors of the breast
    Gatalica, Z
    Finkelstein, S
    Lucio, E
    Tawfik, O
    Palazzo, J
    Hightower, B
    Eyzaguirre, E
    PATHOLOGY RESEARCH AND PRACTICE, 2001, 197 (03) : 183 - 187
  • [32] Methylation of p14ARF gene in meningiomas and its correlation to the p53 expression and mutation
    Amatya, VJ
    Takeshima, Y
    Inai, K
    MODERN PATHOLOGY, 2004, 17 (06) : 705 - 710
  • [33] Analysis of intron 4 of the p53 gene in human cutaneous melanoma
    Shamsher, M
    Montano, X
    GENE, 1996, 176 (1-2) : 259 - 262
  • [34] The role of p53 isoforms' expression and p53 mutation status in renal cell cancer prognosis
    Florijan, Marijana Knezovic
    Ozretic, Petar
    Bujak, Maro
    Pezze, Laura
    Ciribilli, Yari
    Kastelan, Zeljko
    Slade, Neda
    Hudolin, Tvrtko
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2019, 37 (09) : 578.e1 - 578.e10
  • [35] ABSENCE OF P53 MUTATION IN JAPANESE PATIENTS WITH MALIGNANT THYROID LYMPHOMA
    IYOTA, K
    TAKEDA, K
    MATSUZUKA, F
    OKABAYASHI, T
    MORITA, S
    KUMA, K
    HASHIMOTO, K
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1994, 17 (10) : 775 - 782
  • [36] P53 GENE MUTATION SPECTRUM IN HUMAN UNKNOWN PRIMARY TUMORS
    BARELI, M
    ABBRUZZESE, JL
    LEEJACKSON, D
    FROST, P
    ANTICANCER RESEARCH, 1993, 13 (5A) : 1619 - 1623
  • [37] Chemosensitivity of human malignant glioma: modulation by p53 gene transfer
    Martin Trepel
    Peter Groscurth
    Ursula Malipiero
    Erich Gulbins
    Johannes Dichgans
    Michael Weller
    Journal of Neuro-Oncology, 1998, 39 : 19 - 32
  • [38] Profile of p53 gene mutation and abnormal expression of p53 protein in the two types of esophageal cancer.
    Muzeau, F
    Flejou, JF
    Potet, F
    Belghiti, J
    Thomas, G
    Hamelin, R
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 1996, 20 (05): : 430 - 437
  • [39] Chemosensitivity of human malignant glioma: Modulation by p53 gene transfer
    Trepel, M
    Groscurth, P
    Malipiero, U
    Gulbins, E
    Dichgans, J
    Weller, M
    JOURNAL OF NEURO-ONCOLOGY, 1998, 39 (01) : 19 - 32
  • [40] p53 gene mutation in thyroid carcinoma
    Ho, YS
    Tseng, SC
    Chin, TY
    Hsieh, LL
    Lin, JD
    CANCER LETTERS, 1996, 103 (01) : 57 - 63